BLRX:NSD-BioLineRx Ltd (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.78

Change

+0.15 (+5.70)%

Market Cap

USD 0.11B

Volume

0.34M

Average Target Price

USD 20.50 (+637.41%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Hevel Modi'in, Israel.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+12.72 (+8.11%)

USD61.85B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-0.40 (-0.18%)

USD56.98B 21.40 15.53
REGN Regeneron Pharmaceuticals, Inc

+2.06 (+0.41%)

USD54.04B 16.53 12.83
ALXN Alexion Pharmaceuticals, Inc

+1.90 (+1.14%)

USD36.79B 61.23 35.79
BNTX BioNTech SE

+5.62 (+3.60%)

USD36.10B -99,999.99 N/A
BGNE BeiGene, Ltd

+9.25 (+3.16%)

USD27.46B N/A N/A
SGEN Seagen Inc

+2.73 (+1.89%)

USD26.25B 42.96 35.78
RPRX Royalty Pharma plc

+1.34 (+3.23%)

USD25.16B 22.60 15.19
GMAB Genmab A/S

+0.82 (+2.29%)

USD23.17B 26.59 3.31
CVAC CureVac N.V

+2.16 (+1.95%)

USD21.12B N/A N/A

ETFs Containing BLRX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.32% 65% D 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.32% 65% D 55% F
Trailing 12 Months  
Capital Gain 74.84% 69% D+ 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 74.84% 69% D+ 59% F
Trailing 5 Years  
Capital Gain 178.00% 81% B- 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 178.00% 81% B- 79% C+
Average Annual (5 Year Horizon)  
Capital Gain 69.04% 84% B 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 69.04% 84% B 91% A-
Risk Return Profile  
Volatility (Standard Deviation) 147.40% 16% F 9% F
Risk Adjusted Return 46.84% 73% C 68% D+
Market Capitalization 0.11B 19% F 21% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 5.11 46% F 34% F
Price / Cash Flow Ratio -4.62 35% F 67% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -108.36% 25% F 11% F
Return on Invested Capital -65.76% 37% F 13% F
Return on Assets -28.42% 46% F 14% F
Debt to Equity Ratio 12.44% 52% F 70% C-
Technical Ratios  
Short Ratio 0.71 81% B- 74% C
Short Percent N/A N/A N/A N/A N/A
Beta 1.61 39% F 25% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector